In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Listerine With Fluoride Development Continues With “Feedback” Meeting

This article was originally published in The Rose Sheet

Executive Summary

Pfizer Consumer Healthcare plans to conduct a six-month clinical study involving at least 300 subjects to determine whether adding .02% sodium fluoride to the company's Listerine mouthrinse affects the antiplaque/ antigingivitis effectiveness of the product

You may also be interested in...



FreshBurst Listerine Study Must Exhibit 20% Gingivitis Reduction – FDA

A six-month study of FreshBurst Listerine with Fluoride will need to show "a 20% reduction in gingivitis" over a control to merit agency sign-off, FDA told Pfizer execs at an OTC "feedback" meeting Aug. 27

FreshBurst Listerine Study Must Exhibit 20% Gingivitis Reduction – FDA

A six-month study of FreshBurst Listerine with Fluoride will need to show "a 20% reduction in gingivitis" over a control to merit agency sign-off, FDA told Pfizer execs at an OTC "feedback" meeting Aug. 27

Listerine with fluoride meeting postponed

"Feedback" meeting on OTC anticaries drug products monograph slated for June 18 in Rockville, MD will be rescheduled, probably within a month, according to FDA's division of OTC Drug Products. Meeting is part of Pfizer's efforts to amend the monograph to allow a mouthrinse combining essential oils and sodium fluoride (1'The Rose Sheet" June 10, 2002, p. 5). FDA says it needs more time to review relevant materials...

Related Content

UsernamePublicRestriction

Register

RS010357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel